Clinical Trial

CKM For Safe Use of SGLT2i in Type 1 Diabetes

Name: CKM For Safe Use of SGLT2i in Type 1 Diabetes — clinical trial record (NCT07211802)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.

Trial Details

NCT Number	NCT07211802
Lead Sponsor	University of California, San Diego Collaborators: National Institutes of Health (NIH), Abbott, Lexicon Pharmaceuticals, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions	Type 1 Diabetes (T1D)
Enrollment	52 participants
Start Date	2026-07-01
Primary Completion	2030-07-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-08